NASDAQ: CPIX
Cumberland Pharmaceuticals Inc Stock

$5.08+1.32 (+35.11%)
Updated Feb 5, 2025
CPIX Price
$5.08
Fair Value Price
$11.98
Market Cap
$71.33M
52 Week Low
$1.04
52 Week High
$6.43
P/E
-6.6x
P/B
2.88x
P/S
0.49x
PEG
N/A
Dividend Yield
N/A
Revenue
$36.79M
Earnings
-$10.87M
Gross Margin
83.3%
Operating Margin
-27.86%
Profit Margin
-29.6%
Debt to Equity
2.11
Operating Cash Flow
-$1M
Beta
0.25
Next Earnings
Mar 3, 2025
Ex-Dividend
N/A
Next Dividend
N/A

CPIX Overview

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, rheumatology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of chronic and acute constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections. It also develops RediTrex injection for the treatment of active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as disabling psoriasis. In addition, the company is developing ifetroban, a product candidate that is in phase II clinical trial for the treatment of aspirin-exacerbated respiratory disease, systemic sclerosis, and duchenne muscular dystrophy; and has completed phase II clinical trial for the treatment of hepatorenal syndrome and portal hypertension. Further, it develops a clinical program for the use of ifetroban to treat progressive fibrosing interstitial lung diseases; and a product candidate that is in Phase II clinical trial for cholesterol reducing agent to use in the hospital setting. The company was incorporated in 1999 and is headquartered in Nashville, Tennessee.

Zen Rating

Our proven quant model uses 115 proprietary factors, including AI, to determine CPIX's potential to beat the market

CHold
  • Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More

Zen Rating Component Grades

C
Value
C
Growth
C
Momentum
C
Sentiment
C
Safety
C
Financials
D
Artificial Intelligence
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.

Industry: Pharmaceutical

Industry Rating
B
CPIX
Ranked
#36 of 63

Top Ranked Stocks in Industry

View Top Pharmaceutical Stocks

Be the first to know about important CPIX news, forecast changes, insider trades & much more!

CPIX News

Overview

Due Diligence Score

Industry Average (25)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how CPIX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

CPIX ($5.08) is undervalued by 57.61% relative to our estimate of its Fair Value price of $11.98 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
CPIX ($5.08) is significantly undervalued by 57.61% relative to our estimate of its Fair Value price of $11.98 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
CPIX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more CPIX due diligence checks available for Premium users.

Valuation

CPIX fair value

Fair Value of CPIX stock based on Discounted Cash Flow (DCF)

Price
$5.08
Fair Value
$11.98
Undervalued by
57.61%
CPIX ($5.08) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
CPIX ($5.08) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
CPIX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

CPIX price to earnings (PE)

For valuing profitable companies with steady earnings

Company
-6.6x
Industry
9.35x
Market
31.5x

CPIX price to book (PB)

For valuing companies that are loss-making or have lots of physical asset

Company
2.88x
Industry
2.23x
CPIX is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation

CPIX's financial health

Profit margin

Revenue
$9.1M
Net Income
-$1.5M
Profit Margin
-17%
CPIX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
CPIX's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$76.7M
Liabilities
$52.3M
Debt to equity
2.11
CPIX's short-term assets ($35.24M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CPIX's short-term assets ($35.24M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CPIX's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
CPIX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
$475.5k
Investing
$189.6k
Financing
-$536.8k
CPIX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

CPIX vs Pharmaceutical Stocks

TickerZen RatingMarket Cap1d %P/EP/B
CPIXC$71.33M+35.11%-6.60x2.88x
BGMB$76.31M+7.76%-52.80x1.79x
ASRTB$76.86M-1.83%-1.83x0.59x
RMTIB$65.28M-1.94%-40.40x2.24x
INCRC$78.84M+7.45%-4.47x0.64x

Cumberland Pharmaceuticals Stock FAQ

What is Cumberland Pharmaceuticals's quote symbol?

(NASDAQ: CPIX) Cumberland Pharmaceuticals trades on the NASDAQ under the ticker symbol CPIX. Cumberland Pharmaceuticals stock quotes can also be displayed as NASDAQ: CPIX.

If you're new to stock investing, here's how to buy Cumberland Pharmaceuticals stock.

What is the 52 week high and low for Cumberland Pharmaceuticals (NASDAQ: CPIX)?

(NASDAQ: CPIX) Cumberland Pharmaceuticals's 52-week high was $6.43, and its 52-week low was $1.04. It is currently -21% from its 52-week high and 388.46% from its 52-week low.

How much is Cumberland Pharmaceuticals stock worth today?

(NASDAQ: CPIX) Cumberland Pharmaceuticals currently has 14,042,304 outstanding shares. With Cumberland Pharmaceuticals stock trading at $5.08 per share, the total value of Cumberland Pharmaceuticals stock (market capitalization) is $71.33M.

Cumberland Pharmaceuticals stock was originally listed at a price of $16.83 in Aug 11, 2009. If you had invested in Cumberland Pharmaceuticals stock at $16.83, your return over the last 15 years would have been -69.82%, for an annualized return of -7.68% (not including any dividends or dividend reinvestments).

How much is Cumberland Pharmaceuticals's stock price per share?

(NASDAQ: CPIX) Cumberland Pharmaceuticals stock price per share is $5.08 today (as of Feb 5, 2025).

What is Cumberland Pharmaceuticals's Market Cap?

(NASDAQ: CPIX) Cumberland Pharmaceuticals's market cap is $71.33M, as of Feb 7, 2025.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Cumberland Pharmaceuticals's market cap is calculated by multiplying CPIX's current stock price of $5.08 by CPIX's total outstanding shares of 14,042,304.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.